Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

by Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC
Published 2016-02-01